Organisation paid for research Program year 2025 Source: CMS Open Payments

Tanner Memorial Clinic

Neither a doctor nor a teaching hospital

Research payments

$1,133,997

343 payments

Through program year 2025, Tanner Memorial Clinic is reported as receiving $1,133,997 in research payments, across 343 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$125,484	37
2024	Research	$83,648	40
2023	Research	$291,780	66
2022	Research	$215,072	53
2021	Research	$30,377	19
2020	Research	$169,368	89
2019	Research	$218,268	39

Breakdown

Who paid Research payments · program years 2019–2025

Bavarian Nordic A/S $412,736 64 payments
GlaxoSmithKline, LLC. $254,685 137 payments
Seqirus USA Inc $217,008 16 payments
Takeda Pharmaceuticals U.S.A., Inc. $59,651 48 payments
Roche Molecular Systems, Inc. $53,858 14 payments
AbbVie, Inc. $40,125 27 payments
Pfizer Inc. $35,156 9 payments
Regeneron Pharmaceuticals, Inc. $22,614 7 payments
VYNE Pharmaceuticals Inc. $16,901 11 payments
Avanir Pharmaceuticals, Inc. $16,002 4 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $249,770 42 payments
Nct05238025 $162,965 22 payments
A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine QIVc and a United States Licensed Quadrivalent Influenza Virus Vaccine QIV in Healthy Subjects 6 Months Through 47 Months $149,752 5 payments
Menb Rec 2Nd Gen-023 (V72_57) $81,432 48 payments
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects $67,255 11 payments
Phase Iiib, Observer-Blind, Randomized, Placebo-Controlled, Multi-Cent $55,372 30 payments
Rd005662 $53,858 14 payments
A Phase II, Single-Blind, Randomized, Controlled Study to Evaluate the $39,326 29 payments
A Phase 2 Randomized Doubleblind Trial to Evaluate the Safety Tolerability and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants $35,156 9 payments
A Phase 3A, Observer-Blind, Randomized, Controlled Study to Demonstrat $33,861 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.